{"analyses":[{"ciLowerLimit":"0.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.48","estimateComment":"hazard ratio for panitumumab vs cisplatin","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.66","paramType":"Cox Proportional Hazard","paramValue":"0.89","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"32"}],"title":"Death"},{"measurements":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"128"}],"title":"Alive"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"description":"Overall survival is defined as the time interval between the date of randomization to date of death from any cause (calculated in months). Otherwise, survival is censored at the last date that the patient is known to be alive.\n\nNumber of death and alive patients will be reported.","groups":[{"description":"Patients undergo standard fractionation radiotherapy (IMRT or 3D CRT) once daily, 5 days a week, for 7 weeks. Patients receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.\n\ncisplatin: Given IV\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\nintensity-modulated radiation therapy: Patients undergo radiotherapy","id":"OG000","title":"Cisplatin"},{"description":"Patients undergo accelerated fractionation radiotherapy (IMRT or 3D CRT) once or twice daily, 5 days a week, for 6 weeks. Patients receive panitumumab IV over 30-90 minutes 1 week prior to and on days 15 and 36 of radiotherapy.\n\npanitumumab: Given IV\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\naccelerated radiation therapy: Patients undergo accelerated fractionation radiotherapy\n\nintensity-modulated radiation therapy: Patients undergo radiotherapy","id":"OG001","title":"Panitumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6.2 years","title":"Overall Survival Rate","type":"SECONDARY","unitOfMeasure":"Participants"}